niacinamide has been researched along with Cancer of Ovary in 38 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 6.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 6.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "This trial determined the efficacy and tolerability of sorafenib and weekly topotecan in patients with platinum-resistant ovarian cancer (OC) or primary peritoneal carcinomatosis (PPC)." | 5.15 | Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. ( Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C, 2011) |
| "Patients with stage 3 or 4 epithelial ovarian cancer with residual measurable disease or elevated CA-125 levels after maximal surgical cytoreduction were randomized (1:1) to receive treatment with paclitaxel (175 mg/m(2) , 3 h infusion, day 1) and carboplatin (AUC 6." | 2.80 | Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. ( Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC, 2015) |
| "This study was designed to evaluate the response and toxicity of sorafenib alone or when combined with carboplatin and paclitaxel in patients with platinum-sensitive, recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (EOC)." | 2.79 | Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer. ( Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ, 2014) |
| "Treatment with sorafenib was of shorter duration (median 17." | 2.78 | A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. ( Colombo, N; Herzog, TJ; Kim, BG; Lhommé, C; Markowska, J; Oza, A; Petrenciuc, O; Ray-Coquard, I; Scambia, G; Sehouli, J; Shan, M, 2013) |
| "Sorafenib was administered as 400 mg twice daily on days 1-28 of each 4-week cycle." | 2.76 | Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. ( Bodnar, L; Górnas, M; Szczylik, C, 2011) |
| "Sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways through inhibitory effects against MAP kinases and vascular endothelial growth factor receptor-2." | 2.75 | Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. ( Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M, 2010) |
| "Gemcitabine has known activity against EOC." | 2.75 | Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. ( Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ, 2010) |
| " Adverse events included hypertension, hand-foot syndrome, diarrhea, transaminitis, and fatigue." | 2.73 | Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. ( Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ, 2008) |
| "Sorafenib is a non-selective multiple kinase inhibitor with proven antiproliferative effects in thyroid, renal and hepatocellular carcinoma." | 2.50 | Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option. ( Haybaeck, J; Petru, E; Smolle, E; Taucher, V, 2014) |
| "Sorafenib is an unselective inhibitor of multiple kinases which has demonstrated clinical advantage in renal cancer and hepatocellular carcinoma." | 2.49 | Sorafenib for ovarian cancer. ( Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL, 2013) |
| "Epithelial ovarian cancer is the most lethal gynecological malignancy, owing notably to its high rate of therapy-resistant recurrence in spite of good initial response to chemotherapy." | 1.91 | Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer. ( Carmona, E; Leclerc-Desaulniers, K; Lheureux, S; Mes-Masson, AM; Oza, AM; Provencher, DM; Radulovich, N; Rottapel, R; Sauriol, A; Udaskin, ML, 2023) |
| "EGF stimulation of ovarian cancer cells increased cellular migration, mesenchymal transition, CD44 expression and the activation of matrix metalloproteinase (MMP)‑2 and MMP‑9." | 1.46 | Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner. ( Kim, D; Ko, HS; Park, GB, 2017) |
| "Sorafenib is an oral multikinase inhibitor targeting Raf and other kinases." | 1.40 | Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. ( Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y, 2014) |
| "Sorafenib (Nexavar) is a multi-kinase inhibitor that was developed as an inhibitor of RAF-1, in the ERK1/2 pathway, but which was subsequently shown to inhibit class III tyrosine kinase receptors." | 1.40 | Multi-kinase inhibition in ovarian cancer. ( Dent, P, 2014) |
| "Intermittent sorafenib dosing with bevacizumab has promising clinical activity and less sorafenib dose reduction and side effects, but does not ameliorate HFSR." | 1.36 | Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. ( Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J, 2010) |
| "IKKbeta signaling in ovarian cancer regulated the transcription of genes involved in a wide range of cellular effects known to increase the aggressive nature of the cells." | 1.36 | Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. ( Annunziata, CM; Birrer, MJ; Davidson, B; Hernandez, L; Hsu, SC; Kohn, EC, 2010) |
| "Microarray datasets of ovarian cancer cell lines and cancer tissues were analyzed using bioinformatic tools." | 1.36 | Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. ( Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S, 2010) |
| "The NQO activity of ovarian and bladder tumors was determined and the effect of NQO polymorphisms on NQO activity was investigated." | 1.34 | NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. ( Boddy, AV; Edmondson, RJ; Jamieson, D; Knox, R; Leung, HY; Margetts, JP; Pridgeon, S; Wilson, K, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.63) | 18.2507 |
| 2000's | 5 (13.16) | 29.6817 |
| 2010's | 29 (76.32) | 24.3611 |
| 2020's | 3 (7.89) | 2.80 |
| Authors | Studies |
|---|---|
| Sauriol, A | 1 |
| Carmona, E | 1 |
| Udaskin, ML | 1 |
| Radulovich, N | 1 |
| Leclerc-Desaulniers, K | 1 |
| Rottapel, R | 1 |
| Oza, AM | 2 |
| Lheureux, S | 1 |
| Provencher, DM | 1 |
| Mes-Masson, AM | 1 |
| Arend, RC | 1 |
| Davis, AM | 1 |
| Chimiczewski, P | 1 |
| O'Malley, DM | 1 |
| Provencher, D | 1 |
| Vergote, I | 1 |
| Ghamande, S | 1 |
| Birrer, MJ | 3 |
| Kilgour, MK | 1 |
| MacPherson, S | 1 |
| Zacharias, LG | 1 |
| Ellis, AE | 1 |
| Sheldon, RD | 1 |
| Liu, EY | 1 |
| Keyes, S | 1 |
| Pauly, B | 1 |
| Carleton, G | 1 |
| Allard, B | 1 |
| Smazynski, J | 1 |
| Williams, KS | 1 |
| Watson, PH | 1 |
| Stagg, J | 1 |
| Nelson, BH | 1 |
| DeBerardinis, RJ | 1 |
| Jones, RG | 1 |
| Hamilton, PT | 1 |
| Lum, JJ | 1 |
| Duan, P | 1 |
| Fan, L | 1 |
| Gao, Q | 1 |
| Silwal, BM | 1 |
| Ren, M | 1 |
| Shen, Y | 1 |
| Qu, W | 1 |
| Park, GB | 1 |
| Ko, HS | 1 |
| Kim, D | 1 |
| Eckert, MA | 1 |
| Coscia, F | 1 |
| Chryplewicz, A | 1 |
| Chang, JW | 1 |
| Hernandez, KM | 1 |
| Pan, S | 1 |
| Tienda, SM | 1 |
| Nahotko, DA | 1 |
| Li, G | 1 |
| Blaženović, I | 1 |
| Lastra, RR | 1 |
| Curtis, M | 1 |
| Yamada, SD | 2 |
| Perets, R | 1 |
| McGregor, SM | 1 |
| Andrade, J | 1 |
| Fiehn, O | 1 |
| Moellering, RE | 1 |
| Mann, M | 1 |
| Lengyel, E | 1 |
| Yang, H | 1 |
| Li, P | 1 |
| Wang, D | 1 |
| Liu, Y | 1 |
| Wei, W | 1 |
| Zhang, Y | 1 |
| Liu, S | 1 |
| Herzog, TJ | 1 |
| Scambia, G | 1 |
| Kim, BG | 1 |
| Lhommé, C | 1 |
| Markowska, J | 1 |
| Ray-Coquard, I | 1 |
| Sehouli, J | 1 |
| Colombo, N | 1 |
| Shan, M | 1 |
| Petrenciuc, O | 1 |
| Oza, A | 1 |
| Leone Roberti Maggiore, U | 1 |
| Valenzano Menada, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Koshiyama, M | 1 |
| Matsumura, N | 2 |
| Baba, T | 2 |
| Yamaguchi, K | 2 |
| Yoshioka, Y | 1 |
| Konishi, I | 2 |
| Varmira, K | 1 |
| Hosseinimehr, SJ | 1 |
| Noaparast, Z | 1 |
| Abedi, SM | 1 |
| Dent, P | 2 |
| Schwandt, A | 1 |
| von Gruenigen, VE | 1 |
| Wenham, RM | 2 |
| Frasure, H | 1 |
| Eaton, S | 1 |
| Fusco, N | 1 |
| Fu, P | 1 |
| Wright, JJ | 3 |
| Dowlati, A | 1 |
| Waggoner, S | 1 |
| Smolle, E | 1 |
| Taucher, V | 1 |
| Petru, E | 1 |
| Haybaeck, J | 1 |
| Hainsworth, JD | 1 |
| Thompson, DS | 1 |
| Bismayer, JA | 1 |
| Gian, VG | 1 |
| Merritt, WM | 1 |
| Whorf, RC | 1 |
| Finney, LH | 1 |
| Dudley, BS | 1 |
| Devapatla, B | 1 |
| Sharma, A | 1 |
| Woo, S | 1 |
| Webb, T | 1 |
| Carter, J | 1 |
| Roberts, JL | 1 |
| Poklepovic, A | 1 |
| McGuire, WP | 1 |
| Booth, L | 1 |
| AlAli, A | 1 |
| Bushehri, A | 1 |
| Park, JC | 1 |
| Krema, H | 1 |
| Lam, WC | 1 |
| Chen, TC | 1 |
| Yu, MC | 1 |
| Chien, CC | 1 |
| Wu, MS | 1 |
| Lee, YC | 1 |
| Chen, YC | 1 |
| Sociali, G | 1 |
| Raffaghello, L | 1 |
| Magnone, M | 1 |
| Zamporlini, F | 1 |
| Emionite, L | 1 |
| Sturla, L | 1 |
| Bianchi, G | 1 |
| Vigliarolo, T | 1 |
| Nahimana, A | 1 |
| Nencioni, A | 1 |
| Raffaelli, N | 1 |
| Bruzzone, S | 1 |
| Inaba, K | 1 |
| Oda, K | 1 |
| Aoki, K | 1 |
| Sone, K | 1 |
| Ikeda, Y | 1 |
| Miyasaka, A | 1 |
| Kashiyama, T | 1 |
| Fukuda, T | 1 |
| Makii, C | 1 |
| Arimoto, T | 1 |
| Wada-Hiraike, O | 1 |
| Kawana, K | 1 |
| Yano, T | 1 |
| Osuga, Y | 1 |
| Fujii, T | 1 |
| Dalton, HJ | 1 |
| Fleming, ND | 1 |
| Sun, CC | 1 |
| Bhosale, P | 1 |
| Schmeler, KM | 1 |
| Gershenson, DM | 1 |
| Azad, NS | 2 |
| Posadas, EM | 1 |
| Kwitkowski, VE | 1 |
| Steinberg, SM | 2 |
| Jain, L | 1 |
| Annunziata, CM | 4 |
| Minasian, L | 3 |
| Sarosy, G | 1 |
| Kotz, HL | 2 |
| Premkumar, A | 2 |
| Cao, L | 1 |
| McNally, D | 1 |
| Chow, C | 2 |
| Chen, HX | 1 |
| Figg, WD | 1 |
| Kohn, EC | 4 |
| Marquez, CB | 1 |
| Smithberger, EE | 1 |
| Bair, SM | 1 |
| Fenske, NA | 1 |
| Glass, LF | 1 |
| Cherpelis, BS | 1 |
| Brüning, A | 1 |
| Burger, P | 1 |
| Vogel, M | 1 |
| Gingelmaier, A | 1 |
| Friese, K | 1 |
| Burges, A | 1 |
| Lee, JM | 1 |
| Sarosy, GA | 1 |
| Azad, N | 1 |
| Kotz, H | 1 |
| Squires, J | 1 |
| Houston, N | 1 |
| Pölcher, M | 1 |
| Eckhardt, M | 1 |
| Coch, C | 1 |
| Wolfgarten, M | 1 |
| Kübler, K | 1 |
| Hartmann, G | 1 |
| Kuhn, W | 1 |
| Rudlowski, C | 1 |
| Hernandez, L | 1 |
| Hsu, SC | 1 |
| Davidson, B | 1 |
| Welch, SA | 1 |
| Hirte, HW | 1 |
| Elit, L | 1 |
| Schilder, RJ | 2 |
| Wang, L | 1 |
| Macalpine, K | 1 |
| Mandai, M | 1 |
| Okamoto, T | 1 |
| Yamamura, S | 1 |
| Oura, T | 1 |
| Hamanishi, J | 1 |
| Kang, HS | 1 |
| Matsui, S | 1 |
| Mori, S | 1 |
| Murphy, SK | 1 |
| Matei, D | 2 |
| Sill, MW | 2 |
| Lankes, HA | 2 |
| DeGeest, K | 1 |
| Bristow, RE | 1 |
| Mutch, D | 1 |
| Cohn, D | 1 |
| Calvert, V | 1 |
| Farley, J | 1 |
| Petricoin, EF | 1 |
| Bodnar, L | 1 |
| Górnas, M | 1 |
| Szczylik, C | 1 |
| Ramasubbaiah, R | 1 |
| Perkins, SM | 1 |
| Schilder, J | 1 |
| Whalen, C | 1 |
| Johnson, CS | 1 |
| Callahan, M | 1 |
| Jones, T | 1 |
| Sutton, G | 1 |
| Gold, MA | 1 |
| Mannel, RS | 1 |
| Modesitt, SC | 1 |
| Hanjani, P | 1 |
| Bonebrake, AJ | 1 |
| Sood, AK | 1 |
| Godwin, AK | 1 |
| Hu, W | 1 |
| Alpaugh, RK | 1 |
| Kang, HT | 1 |
| Lee, HI | 1 |
| Hwang, ES | 1 |
| Jamieson, D | 1 |
| Wilson, K | 1 |
| Pridgeon, S | 1 |
| Margetts, JP | 1 |
| Edmondson, RJ | 1 |
| Leung, HY | 1 |
| Knox, R | 1 |
| Boddy, AV | 1 |
| Chen, G | 1 |
| Zeller, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane [NCT00791778] | Phase 2 | 246 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors[NCT01202032] | Phase 1 | 36 participants (Anticipated) | Interventional | 2010-07-31 | Completed | ||
| A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma[NCT02330783] | Phase 2 | 106 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.068 |
| Placebo | -0.003 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.045 |
| Placebo | 0.016 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D index ranges from -1.594 (most deterioration from baseline) to 1.594 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.064 |
| Placebo | -0.054 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 3 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -2.225 |
| Placebo | 2.688 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at Cycle 5 minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.947 |
| Placebo | 3.543 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The change is calculated as score at End of treatment minus baseline score. The change in EQ-5D VAS ranges from -100 (most deterioration from baseline) to 100 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -2.147 |
| Placebo | 0.348 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 3 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.086 |
| Placebo | 0.460 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at Cycle 5 minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.223 |
| Placebo | 0.659 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The change is calculated as score at End of treatment minus baseline score. The change in FOSI total score ranges from -32 (most deterioration from baseline) to 32 (most improvement from baseline). (NCT00791778)
Timeframe: Baseline and End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | -0.733 |
| Placebo | -1.088 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied. (NCT00791778)
Timeframe: At Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.727 |
| Placebo | 0.767 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied. (NCT00791778)
Timeframe: At Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.744 |
| Placebo | 0.813 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied. (NCT00791778)
Timeframe: At End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.731 |
| Placebo | 0.741 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00791778)
Timeframe: At Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 73.042 |
| Placebo | 77.899 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00791778)
Timeframe: At Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 75.404 |
| Placebo | 79.915 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00791778)
Timeframe: At End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 71.413 |
| Placebo | 76.246 |
The EQ-5D also contains a VAS, which records the respondent's self-rated health status on a vertical graduated scale. The scale ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). (NCT00791778)
Timeframe: At Cycle 1 (4 weeks per Cycle)/baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 75.235 |
| Placebo | 75.868 |
The EQ-5D contains a descriptive system which measures 5 health dimensions: mobility, self-care, usual activity, pain/discomfort, and anxiety/depression. These five health dimensions are summarized into a single score, the EQ-5D index score which ranges from -0.594 (worst) to 1 (best) when the United Kingdom (UK) weights are applied. (NCT00791778)
Timeframe: At Cycle 1 (4 weeks per Cycle)/baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 0.804 |
| Placebo | 0.779 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic). (NCT00791778)
Timeframe: At Cycle 3 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 25.871 |
| Placebo | 26.105 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic). (NCT00791778)
Timeframe: At Cycle 5 (4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 25.496 |
| Placebo | 26.634 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic). (NCT00791778)
Timeframe: At End of treatment (up to Cycle 33, 4 weeks per Cycle)
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 25.011 |
| Placebo | 24.528 |
The FOSI is an 8-item index derived from the FACT-Ovarian Cancer (FACT-O) to measure symptom response to treatment for ovarian cancer. The FOSI total score ranges from 0 (severely symptomatic) to 32 (asymptomatic). (NCT00791778)
Timeframe: At Cycle 1 (4 weeks per Cycle)/baseline
| Intervention | Scores on a scale (Mean) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 25.909 |
| Placebo | 25.658 |
The OS time was measured from the date of randomization until the date of death due to any cause. Patients who were alive at the time of analysis were censored at the date of the last contact (last time the patient was known to be alive). (NCT00791778)
Timeframe: From randomization of the first patient until 32.5 months later
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | NA |
| Placebo | NA |
Time from randomization to the first documented disease progression by radiological or pathologic assessment or death due to any cause whichever occurred first. For patients who had not progressed or died at the time of analysis, PFS was censored at the date of their last evaluable tumor scan. (NCT00791778)
Timeframe: From randomization of the first patient until 32.5 months later, assessed every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 386 |
| Placebo | 478 |
Time from randomization to the first documented increase of CA-125 above the upper limit of normal. Patients without pathologic CA-125 increase at the time of analysis were censored at their last date of evaluation of CA-125. (NCT00791778)
Timeframe: From randomization of the first patient until 32.5 months later, assessed every 8 weeks
| Intervention | Days (Median) |
|---|---|
| Sorafenib (Nexavar, BAY43-9006) | 337 |
| Placebo | 617 |
3 reviews available for niacinamide and Cancer of Ovary
| Article | Year |
|---|---|
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular | 2017 |
Sorafenib for ovarian cancer.
Topics: Animals; Antineoplastic Agents; Female; Humans; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds | 2013 |
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progressio | 2014 |
12 trials available for niacinamide and Cancer of Ovary
| Article | Year |
|---|---|
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; MA | 2020 |
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; | 2013 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, | 2014 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2015 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Mono | 2008 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Mono | 2008 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Mono | 2008 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Mono | 2008 |
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early T | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Femal | 2010 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Fem | 2011 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relati | 2011 |
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA, Neoplasm; Fallopian Tube Neoplasms; Female; G | 2013 |
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
23 other studies available for niacinamide and Cancer of Ovary
| Article | Year |
|---|---|
Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer.
Topics: Animals; Antineoplastic Agents; Dinucleoside Phosphates; Female; Humans; Mice; Niacinamide; Ovarian | 2023 |
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer.
Topics: Ascites; Female; Humans; Niacinamide; Ovarian Neoplasms; Tumor Microenvironment | 2021 |
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesen | 2017 |
Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Cells, Cultured; Disease Progression; DNA Methylati | 2019 |
Quartz Crystal Microbalance Detection of Poly(ADP-ribose) Polymerase-1 Based on Gold Nanorods Signal Amplification.
Topics: Adenosine Diphosphate Ribose; Biomarkers, Tumor; Cell Line, Tumor; Cetrimonium; Female; Gold; Humans | 2019 |
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, | 2014 |
An improved radiolabelled RNA aptamer molecule for HER2 imaging in cancers.
Topics: Animals; Aptamers, Nucleotide; Cell Line, Tumor; Female; Glycine; Humans; Hydrazines; Indicators and | 2014 |
Multi-kinase inhibition in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niaci | 2014 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Di | 2015 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resi | 2015 |
PIMASERTIB AND SEROUS RETINAL DETACHMENTS.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Fluorescein Angiography; Foll | 2016 |
Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Female; Humans; Imatinib Mesy | 2016 |
Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Topics: 5'-Nucleotidase; Acrylamides; Adenosine Triphosphate; Animals; Cell Line, Tumor; Cytokines; Female; | 2016 |
Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cystadenocarcinoma, Mucinous; Drug | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors | 2017 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined C | 2009 |
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Drug Synergism; | 2010 |
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer.
Topics: Biomarkers, Tumor; Blotting, Western; Carbolines; Cell Adhesion; Cell Movement; Cell Proliferation; | 2010 |
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expressi | 2010 |
Nicotinamide extends replicative lifespan of human cells.
Topics: Adenosine Triphosphate; Carcinoma; Cell Division; Cell Line, Tumor; Cells, Cultured; Cellular Senesc | 2006 |
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Topics: Female; Humans; NAD(P)H Dehydrogenase (Quinone); Niacinamide; Ovarian Neoplasms; Polymorphism, Restr | 2007 |
Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.
Topics: Animals; Cisplatin; Drug Resistance; Female; Niacinamide; Ovarian Neoplasms; Poly(ADP-ribose) Polyme | 1993 |